Atrium Therapeutics, Inc.
RNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002093101
No open-market purchases or sales by Atrium Therapeutics, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $211.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −7 vs. previous quarter
- 154
- 13F valueReported value at the end of Q2 2026
- $211.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RNA, Q2 2026
No superinvestor reported holding RNA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Atrium Therapeutics, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Atrium Therapeutics, Inc. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Atrium Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 1,500,000 | $20.2M | 0.35% | +948,609+172.0% | Added |
| Price T Rowe Associates Inc | 1,472,984 | $19.8M | 0.00% | −80,226−5.2% | Reduced |
| BlackRock, Inc. | 1,447,476 | $19.5M | 0.00% | +242,185+20.1% | Added |
| CRCM LP | 1,283,078 | $17.3M | 5.68% | +1,283,078 | New |
| Arbiter Partners Capital Management LLC | 783,864 | $10.5M | 1.92% | +553,864+240.8% | Added |
| Vanguard Capital Management LLC | 730,831 | $9.83M | 0.00% | +103,962+16.6% | Added |
| TIG Advisors, LLC | 561,533 | $7.55M | 0.35% | −46,019−7.6% | Reduced |
| Cantor Fitzgerald, L. P. | 513,834 | $6.91M | 0.07% | +278,197+118.1% | Added |
| Geode Capital Management, LLC | 386,929 | $5.21M | 0.00% | +67,098+21.0% | Added |
| Two Sigma Investments, LP | 345,481 | $4.65M | 0.00% | +166,921+93.5% | Added |